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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
P2X1-mediated activation of extracellular signal-regulated kinase 2 contributes to
platelet secretion and aggregation induced by collagen
Ce´cile Oury, Emese Toth-Zsamboki, Jos Vermylen, and Marc F. Hoylaerts
Adenosine triphosphate (ATP) and its
stable analog, ,-methylene ATP, acti-
vate the platelet P2X1 ion channel, caus-
ing a rapid Ca influx. Here, we show
that, in washed apyrase-treated platelets,
,-methylene ATP elicits reversible extra-
cellular signal-regulated kinase 2 (ERK2)
phosphorylation through a Ca- and pro-
tein kinase C–dependent pathway. In con-
trast, high-performance liquid chromatog-
raphy-purified adenosine diphosphate
(ADP) did not trigger ERK2 phosphoryla-
tion. ,-Methylene ATP also activated
the ERK2 pathway in P2X1-transfected
HEK293 cells but not in cells expressing
mutated P2X1delL nonfunctional chan-
nels. Because ATP released from the
dense granules during platelet activation
contributes to platelet aggregation elic-
ited by low doses of collagen, and be-
cause collagen causes ERK2 phosphory-
lation, we have investigated the role of
P2X1-mediated ERK2 activation in these
platelet responses. We found that the
antagonism of P2X1 with ADP or desensi-
tization of this ion channel with ,-
methylene ATP both resulted in impaired
ERK2 phosphorylation, ATP secretion,
and platelet aggregation induced by low
concentrations of collagen (< 1 g/mL)
without affecting the minor early dense
granule release. Selective MEK1/2 inhibi-
tion by U-0126 and Ca chelation with
EGTA (ethyleneglycoltetraacetic acid) be-
haved similarly, whereas the PKC inhibi-
tor GF109203-X totally prevented collagen-
induced secretion and ERK2 activation. In
contrast, when elicited by high collagen
concentrations (2 g/mL), platelet aggre-
gation and secretion no longer depended
on P2X1 or ERK2 activation, as shown by
the lack of their inhibition by ,-methyl-
ene ATP or U-0126. We thus conclude that
mild platelet stimulation with collagen
rapidly releases ATP, which activates the
P2X1-PKC-ERK2 pathway. This process
enhances further degranulation of the
collagen-primed granules allowing plate-
let aggregation to be completed. (Blood.
2002;100:2499-2505)
© 2002 by The American Society of Hematology
Introduction
Present in very high concentrations in the platelet-dense gran-
ules, both adenosine diphosphate (ADP) and adenosine triphos-
phate (ATP) are secreted during platelet activation.1 ADP has
long been recognized as an important activator of platelets,
playing an essential role in enhancing secretion, and stabilizing
platelet aggregates induced by other agonists.2 ADP activates 2
receptors (for a review, see Gachet3); P2Y1, coupled to a Gq
protein, is responsible for shape change and initiation of platelet
aggregation, and P2Y12,4 a target for specific antithrombotic
drugs, leads to adenylate cyclase inhibition through a Gi protein
and promotes the completion and amplification of platelet
responses. Recently, ATP was found to be the agonist of the
ionotropic P2X1 receptor, causing a rapid influx of Ca.5,6
Because platelet studies have mainly been performed at low
extracellular Ca concentrations in citrated plasma, but also
due to the difficulties in preserving P2X1 functionality during
platelet handling because of its fast desensitization by spontane-
ously released ATP,7 the function of the platelet P2X1 ion
channel only recently started to be unraveled. Two studies
described the ability of the P2X1 selective agonists, ,-
methylene ATP (,-meATP) and L-,-methylene ATP, to
produce a reversible platelet shape change.8,9 We also provided
evidence for a role of the ion channel in platelet shape change
and aggregation induced by low doses of collagen.9
P2X1 belongs to an emerging family of ionotropic receptors that
are involved in many physiologic processes.10 The ionotropic P2X
receptors regulate intracellular Ca levels through the ligand-
stimulated increase in calcium permeability. However, how these
receptors are linked to intracellular signaling pathways subserving
their biologic actions still is poorly understood. In PC12 cells,
Swanson and coworkers11 have shown that P2X2 mediates the
activation of the extracellular signal-regulated kinase (ERK1/2)
members of the mitogen-activated protein kinase (MAPK) family
of serine/threonine kinases12 via a protein kinase C (PKC)– and
proline-rich tyrosine kinase 2 (PYK2)–dependent pathway.
The prototype ERK pathway consists of a cascade of protein
kinases, Raf1, the MAPK kinase MEK1, and ERK1/2, which
sequentially activate a downstream kinase. In platelets, ERKs have
been shown to be activated after stimulation by thrombin,13
collagen,14 or phorbol esters15 as well as to play a role during
store-mediated Ca entry.16 ERK2 was also shown to be down-
regulated by IIb3 engaged in ligand binding or aggregation,17 and
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a recent study indicated that von Willebrand factor binding to
glycoprotein Ib-IX leads to IIb3 activation via ERK2.18 However,
the upstream effectors and the downstream targets of the platelet
ERK signaling pathway remain largely uncharacterized.
In this study, we found that ,-meATP elicits reversible ERK2
phosphorylation through a Ca- and PKC-dependent pathway.
We showed that the minor early ATP secretion evoked by low
concentrations of collagen activates the P2X1-mediated Ca
influx leading to ERK2 phosphorylation. The P2X1-PKC-ERK2
pathway plays a role in amplifying dense granule release, an event




ADP, adenosine 5-(,-methylene) triphosphate (,-meATP), adenosine
2-phosphate 5-phosphate (A2P5P), and indomethacin were from Sigma
(St Louis, MO). ARC-69931MX was a gift from Astra Zeneca RD
(Charnwood, United Kingdom).19 Collagen (collagen reagent horm) was
from Nycomed (Munich, Germany). U-0126 and GF109203-X were
purchased from Biomol Research Laboratories (Plymouth Meeting, PA).
ADP and ,-meATP were purified by high-performance liquid chromatog-
raphy (HPLC) on an Adsorbosphere HS C18, 7 m, 250  4.6 mm, column
(Alltech, Bad Segeberg, Germany) as described.9
Preparation of hirudinized PRP and washed platelets
Blood freshly drawn from healthy donors was mixed with 20 g/mL
hirudin in saline, centrifuged at 150g for 15 minutes, and the platelet-rich
plasma (PRP) was collected. The platelet counts were adjusted to 2.5  105
platelets/L with autologous platelet-poor plasma (PPP). For the prepara-
tion of washed platelets, blood was collected on acid-citrate-dextrose
(ACD; 93 mM sodium citrate, 7 mM citric acid, 0.14 mM dextrose, pH 6.5)
in a volume ratio of ACD to blood of 1:6, and centrifuged for 15 minutes at
150g in the presence of apyrase (1 U/mL, grade I; Sigma), when indicated.
The PRP was then diluted 3-fold in apyrase-containing ACD, and centri-
fuged for 10 minutes at 800g. The platelet pellet was then resuspended in
Tyrode buffer (137 mM NaCl, 12 mM NaHCO3, 2 mM KCl, 0.34 mM
Na2HPO4, 1 mM MgCl2, 5.5 mM glucose, and 5 mM HEPES [N-2-
hydroxyethylpiperazine-N-2-ethanesulfonic acid], pH 7.3) containing 0.35%
human serum albumin and 1 U/mL apyrase, at a density of 2.0  105
platelets/L. CaCl2 (2 mM) was added prior to the agonists unless indicated
differently.
Platelet aggregation and ATP secretion analyses
Light transmission during collagen-induced platelet aggregation was re-
corded in hirudinized PRP or apyrase-treated washed platelets on a
Chrono-Log Aggregometer (Havertown, PA). ATP secretion was monitored
in hirudinized PRP or in washed platelets in parallel with platelet
aggregation by adding firefly luciferase and luciferin and comparing the
luminescence generated by platelet ATP release or by an ATP standard
(Kordia, Leiden, The Netherlands). P2X1 desensitization occurs within a
few milliseconds; therefore desensitization could be accomplished by
adding ,-meATP (0.5 M) simultaneously with collagen to prevent
released ATP from activating the ion channel.7 P2X1 antagonism was
achieved by adding ADP (0.5 M) 1 minute prior to collagen.9 The
MEK1/2 inhibitor U-0126, the PKC inhibitor GF109203-X, or vehicle was
added 2 minutes prior to collagen. EGTA (ethylene glycol tetraacetic acid)
was added 5 minutes prior to collagen. At least 3 independent experiments
were performed on platelets from different individuals. The data are
represented as the mean  SEM. Statistical analysis of the data were made
using nonpaired Student t test.
Phospho-ERK1/2 detection
Serum-starved stable P2X1- and P2X1delL-expressing HEK293 cells
(0.5  105 cells),20 or stirred washed platelets (0.3-mL aliquots) that had
been treated with apyrase (1 U/mL) for 30 minutes, were stimulated with
agonists at 37°C. The reaction was stopped by the addition of sodium
dodecyl sulfate (SDS) sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% SDS,
10% glycerol, 50 mM dithiothreitol, 0.1% bromophenol blue). Then 40-L
sample aliquots were loaded on SDS–polyacrylamide gel electrophoresis
(SDS-PAGE; 10%) and subjected to Western blotting using the Phospho-
Plus p44/42 MAP kinase antibody kit (New England Biolabs, Hitchin,
United Kingdom) according to the instructions of the manufacturer. The
data are representative of at least 3 independent experiments performed on
different cell extracts or on platelets from different individuals.
Results
P2X1 stimulation selectively causes Ca- and PKC-dependent
ERK2 activation
We have investigated the intracellular signaling pathways selec-
tively activated through P2X1 and that could subserve the role of
this ion channel during platelet activation. We found that in
apyrase-treated washed platelets, ,-meATP (2 M) caused rapid
and reversible ERK2 phosphorylation (about 5-fold stimulation),
reaching a maximum at 2 minutes and disappearing after 10
minutes (Figure 1A). Figure 1B shows the dose response to this
agonist, which is in agreement with the previously described
concentrations for ,-meATP–induced platelet shape change.9
The ,-meATP–elicited ERK2 phosphorylation was fully inhib-
ited by GF109203-X, an inhibitor of the , , , and 	 isoforms of
PKC and by the highly specific MEK inhibitor, U-0126 (Figure
2A). ERK2 phosphorylation also required extracellular Ca
because it no longer occurred in the presence of EGTA (Figure 2B)
and was almost absent when no extracellular Ca was added (data
not shown). HPLC-purified ADP (from 0.5 up to 20 M) was
unable to induce ERK2 phosphorylation at any time point (Figure
2C). These data revealed that, in platelets, the P2X1-mediated Ca
influx activates a PKC-dependent ERK2 signaling pathway.
Figure 1. P2X1 mediates ERK2 phosphorylation in platelets. Western blot
analyses of ,-meATP–induced ERK2 phosphorylation in apyrase-treated washed
platelets using Phospho-ERK1/2 MAP kinase (P-ERK2) and control MAP kinase
(ERK2, lower panels) antibodies. (A) Time course of 2 M ,-meATP–induced
ERK2 phosphorylation. (B) Platelets were stimulated with increasing concentrations
of ,-meATP for 2 minutes.
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The dominant-negative P2X1delL mutant is unable to
activate ERK2
We have previously identified and characterized a nonfunctional
dominant-negative mutant of P2X1 (P2X1delL).20 To further dem-
onstrate the ability of the P2X1-elicited Ca influx to selectively
activate the ERK2 pathway, apyrase-treated HEK293 cells stably
expressing either the normal P2X1 protein (P2X1wt) or P2X1delL
were stimulated with ,-meATP for 2 minutes before analyzing
ERK phosphorylation. ,-meATP induced phosphorylation of
ERK1/2 in P2X1wt-expressing cells but not in cells expressing the
nonfunctional P2X1delL channels (Figure 3). The nontransfected
cells did not respond to ,-meATP (data not shown). These results
thus established a direct correlation between the presence of
functional P2X1 channels, triggering Ca influx, and the activa-
tion of ERK.
Inhibition of P2X1 or ERK2 activation impairs dense granule
release in platelets stimulated with low concentrations
of collagen
Collagen-induced platelet aggregation largely depends on secre-
tion, and the importance of ADP, acting at P2Y1 and P2Y12, is well
documented.3 We recently reported that P2X1, through secreted
ATP, is also required for platelet aggregation elicited by low doses
of collagen.9 We wanted to determine whether the P2X1-PKC-
ERK2 signaling pathway plays a role in this process. Therefore, we
have recorded ATP secretion in parallel with platelet aggregation
and analyzed the effects of P2X1 desensitization and MEK
inhibition on these platelet responses. These recordings were
performed in hirudinized PRP to maintain physiologic Ca
concentrations and preserve enough P2X1 functionality for the
purpose of the experiment. Despite the fact that ,-meATP could
not induce ATP release by itself, these analyses revealed that both
P2X1 desensitization with ,-meATP and MEK inhibition by
U-0126 potently impaired ATP release triggered by low doses of
collagen (0.4-1g/mL). Collagen (0.5g/mL) induced 4.29  0.22
M ATP release (Figure 4), which was reduced to 0.14  0.08 M
(n 
 7, P  .0001) in the presence of ,-meATP (Figure 4), and
Figure 4. Role of P2X1-mediated ERK2 activation in platelet ATP secretion and
aggregation induced by low concentrations of collagen. Parallel recordings of
light transmission (%) and ATP secretion (M) in hirudinized PRP during platelet
stimulation with 0.5 g/mL collagen alone (control), in the presence of 0.5 M
,-meATP, after a 2-minute preincubation with 1 M U0126, or in the presence of 10
mM EGTA, as indicated. Arrows represent the time of application of collagen. Dashed
arrows indicate the moment of initial detection of ATP during platelet aggregation.
Percentages of light transmission, the concentrations of ATP released, and the time
bar are included.
Figure 2. The P2X1-mediated ERK2 phosphorylation depends on Ca and
PKC. Western blot analyses of ,-meATP–induced ERK2 activation in apyrase-
treated washed platelets using the same antibodies as in Figure 1. (A) ,-meATP–
induced ERK2 activation was analyzed after 2 minutes with or without 2 minutes of
preincubation with the MEK inhibitor U-0126 (1 M) or the PKC inhibitor GF109203-X
(10 M), as indicated. (B) Dose response to ,-meATP in the presence of 5 mM
EGTA. (C) Platelets were stimulated for 2 minutes with 5 M ADP.
Figure 3. Selective P2X1-mediated ERK2 phosphorylation in transfected HEK293
cells. Western blot analyses of ERK1/2 phosphorylation in apyrase-treated HEK293
cells, stably expressing normal P2X1 (P2X1wt) or its dominant-negative P2X1delL
mutant. ERK1/2 activation was induced with 100 M ,-meATP in the presence of 2
mM CaCl2.
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to 0.35  0.08 M (n 
 4, P  .0001) by U-0126 (Figure 4).
Because in the Ca-rich environment of hirudinized PRP, indo-
methacin only slightly inhibited the collagen-induced platelet
aggregation (data not shown), no major role in aggregation is
attributed to thromboxane A2. Therefore, the inhibition of platelet
aggregation by U-0126 is not due to nonselective inhibition of
cyclooxygenase.21 Consistent with an event requiring Ca influx
through P2X1, ATP secretion was similarly inhibited in the
presence of the Ca chelator EGTA (0.56  0.11 M, n 
 3;
Figure 4). In contrast, neither ,-meATP nor U-0126 affected
platelet ATP secretion and aggregation evoked by higher concentra-
tions of collagen (2 g/mL; data not shown); likewise, EGTA only
slightly impaired ATP secretion induced by 2 g/mL collagen (data
not shown). These data thus suggest an essential role for the
P2X1-PKC-ERK2 signaling pathway in enhancing dense granule
release and completing platelet aggregation initiated by low doses
of collagen.
The P2X1-PKC-ERK2 signaling pathway is not involved in the
early collagen-induced secretion
Platelets stimulated with collagen release ATP before the onset of
shape change22 (Figure 4). This early release was totally blocked by
the PKC inhibitor GF109203-X (not shown), which also abolished
collagen-induced platelet shape change and aggregation (Figure
5A). The inhibition of collagen-induced platelet shape change by
the P2Y1 receptor antagonist A2P5P was indicative of the involve-
ment of secreted ADP (data not shown). We then wondered whether
this early secretion responsible for platelet shape change precedes
or depends on the activation of the P2X1-PKC-ERK2 signaling
pathway. Figure 4 revealed that neither ,-meATP nor U-0126
and EGTA were able to fully inhibit ATP release induced by
collagen (0.5 g/mL), and platelet shape change occurred nor-
mally. Accordingly, the ATP release induced by 0.3 g/mL collagen
(0.33  0.05 M, n 
 3), which elicited platelet shape change
without causing aggregation (data not shown), was not affected by
these treatments either (data not shown). These results indicate that
the PKC-ERK2 pathway is not involved in the early secretion
preceding platelet shape change, and further indicate that activation
of this pathway is secondary to the action of the limited amount of
ATP secreted during the initial response of platelets to collagen.
At low-dose collagen, ERK2 phosphorylation
is mediated via P2X1
In platelets, collagen activates the ERK signaling pathway.14 To
further investigate the contribution of P2X1 to this pathway, we
have analyzed the effect of P2X1 desensitization on the ability of
collagen to cause ERK2 phosphorylation in apyrase-treated washed
platelets. Platelet aggregation was recorded in parallel. In apyrase-
treated washed platelets, similarly as in hirudinized PRP, P2X1
desensitization with ,-meATP (0.5 M) inhibited platelet aggre-
gation induced by low concentrations of collagen (0.75-1 g/mL;
Figure 5A). Western blot analyses indicated that the collagen
(0.75-1 g/mL)–induced ERK2 phosphorylation reaches a maxi-
mum after 4 minutes following addition of the agonist (Figure 5B);
the appearance of ERK2 phosphorylation at minute 2 correlated
with the onset of platelet aggregation (Figure 5A,B). Interestingly,
P2X1 desensitization with ,-meATP (0.5 M), able to inhibit
platelet aggregation, also led to the loss of ERK2 phosphorylation
at the time where maximal activation occurred in the control (4
minutes; Figure 5A,B), even despite the fact that ,-meATP is
capable of triggering ERK2 phosphorylation itself (Figure 1). We
then used a low concentration of ADP (0.5 M) that selectively
antagonizes the ATP-induced activation of P2X1 as well as the
,-meATP-evoked platelet shape change9 without causing ERK2
phosphorylation (Figure 2C). Similarly as ,-meATP, ADP pre-
treatment prevented the collagen-induced ERK2 phosphorylation
(Figure 5C) as well as platelet aggregation (Figure 5A and Oury et
al9). These results show that the observed inhibition of ERK2
activation can be caused both by P2X1 antagonism (ADP) and
desensitization (,-meATP), the 2 P2X1 neutralizing approaches
leading to impaired platelet aggregation. The collagen-induced
ERK2 activation and aggregation were also abolished in the
presence of EGTA (Figure 5A,C), supportive of the involvement of
P2X1-mediated Ca influx (Figure 2B). The PKC inhibitor
GF109203-X that prevents platelet secretion (data not shown),
shape change, and aggregation evoked by collagen (Figure 5A),
and the ,-meATP–elicited ERK2 activation (Figure 2A), inhib-
ited ERK2 activation caused by collagen, as expected (Figure 5C).
The inhibition of collagen-induced ERK2 phosphorylation by
U-0126 (Figure 6B) equally blocked platelet aggregation (Figure
5A), confirming the importance of the P2X1-ERK2 pathway, also
when studied in apyrase-treated washed platelets. The further
inhibition of U-0126–treated platelets with GF109203-X abolished
platelet shape change and residual ATP secretion (data not shown),
Figure 5. Activation of ERK2 at low concentrations of collagen depends on
P2X1; correlation between ERK2 phosphorylation and platelet aggregation. (A)
Light transmission (%) recordings in apyrase-treated washed platelets stimulated
with collagen (1 g/mL) alone (control), in the presence of 0.5 M ,-meATP, or after
preincubation with 0.5 M ADP, 1 M U-0126, 5 mM EGTA, 10 M indomethacin, or
10 M GF109203-X, as indicated. Time bar is included. (B) Parallel Western blot
analyses of ERK2 phosphorylation in these platelet samples. The time course of
ERK2 phosphorylation induced by 1 g/mL collagen alone or in the presence of 0.5
M ,-meATP is shown. (C) The ERK2 phosphorylation detected in platelets
stimulated with the same concentration of collagen for 4 minutes in the presence or
absence of ,-meATP, ADP, EGTA, GF109203-X, or indomethacin, as indicated.
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confirming that the minor early dense granule release occurs
independently of ERK2. Platelet aggregation was prevented by the
P2Y12 antagonist ARC-69931MX in agreement with a role for
secreted ADP (data not shown), and was also inhibited by
indomethacin (Figure 5A), indicative of a contribution of synthe-
sized thromboxane A2 during the process of aggregation of washed
platelets performed in the presence of apyrase. The relative
contribution of thromboxane A2 during aggregation of apyrase-
treated washed platelets thus differs from that studied in hirudi-
nized PRP. Nevertheless, indomethacin (Figure 5C) did not affect
ERK2 phosphorylation, showing that thromboxane A2 is not
involved in the activation of the ERK2 pathway. Our data thus
indicate that ERK2 phosphorylation induced by low doses of
collagen depends on the action of secreted ATP at P2X1, contribut-
ing to the completion of platelet aggregation.
Platelet aggregation induced by high doses of collagen no
longer depends on P2X1 and ERK2 activation
Desensitization of P2X1 with ,-meATP did not inhibit ERK2
phosphorylation and aggregation of washed apyrase-treated plate-
lets in response to high concentrations of collagen (2 g/mL;
Figure 6A,B). Similarly, collagen-induced ERK2 activation was no
longer inhibited in the presence of EGTA (Figure 6B), showing
that, in agreement with the absence of inhibition by ,-meATP, no
role can be attributed to P2X1 in these conditions of strong platelet
stimulation. Interestingly, total blockade of the ERK pathway by
U-0126 (Figure 6B) had no effect on platelet aggregation induced
by the high concentration of collagen (Figure 6A). These data thus
indicate that, at high doses of collagen, platelet aggregation occurs
independently of the P2X1-ERK2 pathway. These results also show
that, at high collagen concentrations, platelet aggregation and
ERK2 phosphorylation can be dissociated, ERK2 no longer being
involved in secretion reactions leading to platelet aggregation.
Discussion
In the present study, we have identified the ERK2 signaling
pathway as an intracellular mechanism subserving the function of
the ATP-gated P2X1 ion channel during platelet aggregation
induced by low concentrations of collagen. We have shown that the
P2X1-mediated ERK2 activation is a Ca- and PKC-dependent
process needed to amplify dense granule release initiated by
this agonist.
In a previous study, we provided evidence that during collagen-
initiated platelet activation, the early secretion of ATP results in the
activation of P2X1 acting as a positive regulator of subsequent
platelet responses.9 To investigate the role of the P2X1-PKC-ERK2
pathway in collagen-induced platelet aggregation, we took advan-
tage of the possibility to selectively antagonize ATP-induced P2X1
activation with ADP9 and to prevent Ca influx through the ion
channel via chelation of extracellular Ca by EGTA. ,-meATP
was used to specifically desensitize P2X1 during platelet stimula-
tion by collagen,7,9 and the total blockade of the ERK pathway was
achieved by U-0126, a highly specific inhibitor of the MAPK
kinases MEK1/2. It appeared that all these inhibitory strategies
similarly prevented ERK2 phosphorylation, platelet-dense granule
release, and aggregation induced by low doses of collagen. Our
data indicate that P2X1 and ERK2 are proximal and distal
components, respectively, of a contiguous regulatory signaling
pathway participating in platelet responses to collagen.
Collagen appeared to evoke the secretion of ATP (and ADP)
rapidly, prior to the onset of shape change. The collagen-induced
platelet shape change was found to depend on secretion, because it
was inhibited by the PKC inhibitor, GF109203-X, which totally
prevents secretion elicited by this agonist; shape change was also
inhibited by the P2Y1 antagonist, A2P5P. In contrast, neither EGTA
nor the MEK1/2 inhibitor U-0126 affected this platelet shape
change, therefore excluding a role for the P2X1-PKC-ERK2
signaling pathway in the very early dense granule release triggered
by collagen. This indicates that another PKC-dependent secretory
pathway is responsible for the minor early collagen-induced
secretion.
Combining these findings, in the model depicted in Figure 7, we
propose a P2X1-dependent mechanism essential for the completion
of platelet aggregation induced by low doses of collagen. Accord-
ing to this model, platelet stimulation with low doses of collagen
rapidly causes ERK2-independent minor dense granule release
(step 1); ATP secreted during this early event activates the
P2X1-PKC-ERK2 pathway (step 2), which is needed to complete
platelet aggregation by enhancing the release reaction from collagen-
primed dense granules (step 3). The notion of dense granule
priming refers to our finding that, on one hand, the minor early
release induced by collagen (activation of PKC1) is insufficient to
cause platelet aggregation unless the P2X1-PKC2-ERK2 pathway
is activated; on the other hand, the sole activation of the latter
pathway with ,-meATP is unable to release granule contents,
unless collagen has initiated the process. Activation of PKC1
triggers minor early dense granule release but does not cause direct
ERK2 phosphorylation. Thus, ERK2 activation and platelet aggre-
gation evoked by low concentrations of collagen do not occur
Figure 6. Platelet aggregation induced by high concentrations of collagen does
not depend on the ERK2 pathway. (A) Light transmission (%) recordings in
apyrase-treated washed platelets stimulated with 2 g/mL collagen alone (control), in
the presence of 0.5 M ,-meATP, or after preincubation with 1 M U-0126, as
indicated. Time bar is included. (B) Parallel Western blot analyses of ERK2
phosphorylation in these platelet samples. ERK2 phosphorylation was induced by 1
or 2 g/mL collagen for 4 minutes alone or after preincubation with 1 M U-0126 or 5
mM EGTA, as indicated; ERK2 phosphorylation was also analyzed after platelet
stimulation for 4 minutes with 2 g/mL collagen alone or in the presence of 0.5 M
,-meATP.
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independently of P2X1, and the collagen-induced secretion re-
quired to complete platelet aggregation is the result of sequential
activation of 2 distinct PKC-dependent pathways (steps 1 and 2).
Our model describes the role of the P2X1-PKC-ERK2 pathway
during platelet activation with low concentrations of collagen. The
fact that desensitization of P2X1 can no longer inhibit the collagen-
induced ERK2 phosphorylation, ATP secretion, and aggregation
when platelets are activated with higher concentrations of collagen
implies that ERK can be activated via alternative pathways;
because the blockade of the ERK pathway by U-0126 no longer
inhibited the collagen-induced platelet aggregation, it appears that
ERK activation no longer plays an important role in aggregation
under those conditions. Platelet aggregation progressively relies
more on the engagement of other activation pathways, such as
production of thromboxane and other secreted products.
The inability of HPLC-purified ADP to activate ERK2 is in
agreement with a previous study in which ADP was rather linked to
p38 MAPK phosphorylation through P2Y1.23 Because p38 MAPK
is not phosphorylated following P2X1 stimulation (data not shown),
it seems that the 2 MAPK pathways, ERK and p38 MAPK, are
differentially triggered by ATP and ADP, respectively. Here, the
selectivity of the P2X1-ERK2 cascade was further demonstrated in
HEK293 cells heterologously expressing P2X1 or its dominant-
negative mutant P2X1delL.20 Indeed, only those cells expressing
functional P2X1 channels were able to activate ERKs in response to
,-meATP. Therefore, the use of P2X1delL allowed us to establish
a direct relation between the presence of functional P2X1 channels
in the cell membrane and the activation of the ERK2 signaling
pathway.
Despite the biologic significance of secretion for platelet
function, the molecular mechanisms governing secretion are only
partially understood.24,25 Although the ERK pathway has been
implicated in secretion processes in other cell types,26 how ERK
activation could be linked to the cellular secretory machinery
remains to be investigated. Interestingly, we found that, although
,-meATP and collagen are both capable of causing ERK2
phosphorylation, the faster ERK2 phosphorylation elicited by
,-meATP is abrogated by simultaneous addition of collagen.
Conversely, the collagen-induced ERK2 phosphorylation is dis-
turbed by ,-meATP and constitutes the biochemical basis for the
inhibition of collagen-induced platelet aggregation, underlying the
P2X1 desensitization approach. These findings also emphasize the
importance of the kinetics of P2X1-mediated ERK2 phosphoryla-
tion for platelet activation, compatible with a strict necessity to
sequentially trigger several components of the platelet secretion
machinery (Figure 7).
In other tissues, P2X-type receptors have also been shown to
play a role in secretion. Thus, in cardiac sympathetic nerve endings,
ATP appeared to induce norepinephrine release by acting at P2X
receptors27; in the RBA-2 type-2 astrocyte cell line, ATP stimulates
-aminobutyric acid (GABA) release through the P2X7 receptor,
PKC, PKA, MEK/ERK, and phospholipase D28; in the guinea pig
vas deferens, P2X1 mediates ATP release and contraction29; ,-
meATP–sensitive P2X receptors play a significant role in modulat-
ing excitatory sensory synaptic transmission in the spinal cord by
enhancing glutamate release.30
Our data that the P2X1-activated secretion involves PKC is in
agreement with the study by Yoshioka et al31 who identified PKC
as an essential cytosolic factor for the Ca-induced secretion from
both  and dense granules in platelets. Whether the Ca-
calmodulin–dependent protein cascade, known also to be involved
in platelet secretion,32 plays a role in the P2X1-activated process,
still has to be determined.
In conclusion, we provide evidence for a distinct role of the
P2X1 ion channel in the amplification of platelet granule release
initiated by low doses of collagen; this amplification occurs via
selective activation of a PKC-dependent ERK2 signaling pathway.
These results support the notion that platelet activation by this
agonist leads to a concomitant signaling both through the ADP
receptors P2Y1 and P2Y12, and the ATP-gated ion channel P2X1.
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